694 related articles for article (PubMed ID: 31100252)
21. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
[TBL] [Abstract][Full Text] [Related]
22. Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project.
Hurle R; Colombo P; Lazzeri M; Lughezzani G; Buffi NM; Saita A; Elefante GM; Morenghi E; Forni G; Cardone P; Lista G; Maffei D; Guazzoni G; Casale P
Eur Urol Oncol; 2018 Oct; 1(5):437-442. PubMed ID: 31158085
[TBL] [Abstract][Full Text] [Related]
23. A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.
Huang H; Liu A; Liang Y; Xin Y; Liu J; Hao Y; Huang D; Chen L; Li W; Jiang G; Huang Y; Xu Y; Zhang J; Ma T; Xu D; Gao Y
BMC Med; 2023 Sep; 21(1):357. PubMed ID: 37726806
[TBL] [Abstract][Full Text] [Related]
24. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
25. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology.
Odisho AY; Berry AB; Ahmad AE; Cooperberg MR; Carroll PR; Konety BR
Eur Urol; 2013 May; 63(5):936-40. PubMed ID: 22521093
[TBL] [Abstract][Full Text] [Related]
26. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
Fantony JJ; Longo TA; Gopalakrishna A; Owusu R; Lance RS; Foo WC; Inman BA; Abern MR
Cancer Biomark; 2017; 18(4):381-387. PubMed ID: 28106542
[TBL] [Abstract][Full Text] [Related]
27. The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.
Pierconti F; Martini M; Cenci T; Fiorentino V; Gianfrancesco LD; Ragonese M; Bientinesi R; Rossi E; Larocca LM; Racioppi M; Bassi PF
Urol Oncol; 2022 Mar; 40(3):108.e19-108.e25. PubMed ID: 34903453
[TBL] [Abstract][Full Text] [Related]
28. Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck® as a diagnostic tool in upper urinary tract tumor.
Palermo M; D'Elia C; Trenti E; Comploj E; Mian C; Schwienbacher C; Heidegger I; Clauser S; Pycha A; Vjaters E
Minerva Urol Nephrol; 2024 Apr; 76(2):195-202. PubMed ID: 38498297
[TBL] [Abstract][Full Text] [Related]
29. Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.
Fiorentino V; Pizzimenti C; Franchina M; Rossi ED; Tralongo P; Carlino A; Larocca LM; Martini M; Fadda G; Pierconti F
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569864
[TBL] [Abstract][Full Text] [Related]
30. The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer.
Ragonese M; Gianfrancesco LD; Palermo G; Pierconti F; Martini M; Foti M; Bassi P; Racioppi M
Clin Genitourin Cancer; 2022 Aug; 20(4):e271-e275. PubMed ID: 35871875
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
[TBL] [Abstract][Full Text] [Related]
32. Methylation study of the Paris system for reporting urinary (TPS) categories.
Pierconti F; Martini M; Cenci T; Fiorentino V; Sacco E; Bientinesi R; Pugliese D; Iacovelli R; Schinzari G; Larocca LM; Bassi PF
J Clin Pathol; 2021 Feb; 74(2):102-105. PubMed ID: 32527754
[TBL] [Abstract][Full Text] [Related]
33. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma.
Mansoor I; Calam RR; Al-Khafaji B
Anal Quant Cytol Histol; 2008 Feb; 30(1):25-32. PubMed ID: 18459584
[TBL] [Abstract][Full Text] [Related]
34. [Clinical usefulness of the ImmunoCyt urinary test in the follow-up protocol of patients with urothelial neoplasms].
García Peñalver C; Pérez Barrios A; Leiva Galvis O
Actas Urol Esp; 2005 Jun; 29(6):535-41. PubMed ID: 16092675
[TBL] [Abstract][Full Text] [Related]
35. Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.
Hekman MCH; Wijn SRW; Lotan Y; Govers TM; Witjes JA
World J Urol; 2023 Feb; 41(2):471-476. PubMed ID: 36534153
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.
Konety B; Shore N; Kader AK; Porten S; Daneshmand S; Lough T; Lotan Y
Eur Urol; 2019 Aug; 76(2):238-243. PubMed ID: 31103391
[TBL] [Abstract][Full Text] [Related]
37. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
38. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Arndt C; Barski D; Otto T; Gerullis H
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513851
[TBL] [Abstract][Full Text] [Related]
39. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
[TBL] [Abstract][Full Text] [Related]
40. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O
World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
